Donor safety: The role of the WMDA in ensuring the safety of volunteer unrelated donors: Clinical and ethical considerations

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 832-838

  Shaw, B E ^a   Ball, L ^b   Beksac, M ^c   Bengtsson, M ^d   Confer, D ^e   Diler, S ^f   Fechter, M ^g   Greinix, H ^h   Koh, M ⁱ   Lee, S ^j   Nicoloso De Faveri, G ^k   Philippe, J ^l   Pollichieni, S ^m   Pulsipher, M ⁿ   Schmidt, A ^o   Yang, E ^p   Van Walraven, A M ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ANKARA UNIVERSITY   (Turkey)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e NATIONAL MARROW DONOR PROGRAM   (United States)

^f ISTANBUL UNIVERSITY   (Turkey)

^g Europdonor Foundation   (Netherlands)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ ST GEORGE S HOSPITAL   (United Kingdom)

^j Fred Hutchinson Cancer Research Center   (United States)

^k Swiss Blood Stem Cells   (Switzerland)

^l OneMatch Stem Cell and Marrow Network   (Canada)

^m GALLIERA HOSPITAL   (Italy)

ⁿ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^o DKMS German Bone Marrow Donor Center   (Germany)

^p Institute of Human Genetics   (Taiwan)

more..

Author keywords

Donor; Safety; WMDA

Indexed keywords

CELL ISOLATION; CLINICAL PRACTICE; CONFIDENTIALITY; DONOR SELECTION; EXPECTATION; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH STATUS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFORMED CONSENT; LIVING DONOR; MEDICAL ASSESSMENT; MEDICAL ETHICS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REGISTER; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; SAFETY; UNRELATED DONOR; VOLUNTEER; WORLD MARROW DONOR ASSOCIATION;

HEALTH CARE COALITIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERNATIONALITY; REGISTRIES; SAFETY; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952428879     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.2     Document Type: Review

References (25)

1. Goldman JM. A special report: bone marrow transplants using volunteer donors-recommendations and requirements for a standardized practice throughout the world-1994 update. The WMDA Executive Committee. Blood 1994;84:2833-2839.
2. Bakken R, van Walraven AM, Egeland T. Donor commitment and patient needs. Bone Marrow Transplant 2004;33:225-230.
3. Rosenmayr A, Hartwell L, Egeland T. Informed consent-suggested procedures for informed consent for unrelated haematopoietic stem cell donors at various stages of recruitment, donor evaluation, and donor workup. Bone Marrow Transplant 2003;31:539-545.
4. Duffy M, Coffey K. Confidentiality donor-patient. http://www.worldmarrow. org/fileadmin/WorkingGroups-Subcommittees/EWG/Confidentiality-EWG-2008pdf. Accessed on 13 January 2010.
5. http://www.jacie.org/portal/jacie/standards. Accessed on 13 January 2010.
6. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008;42:9-14.
7. Egeland T, Lie J, Persson U, Raymond J, Muller C. Donor and liability insurance of donor registries, donor centers, and collection centers-recommendations. Bone Marrow Transplant 2004;33:467-470.
8. Heard P, Hartwell L, Greinix H. Patient consent to donor terms and transplant centre expectations. http://www.worldmarrow.org. Accessed on 13 January 2010.
9. BSBMT. http://www.bsbmt.org/pages/64-Indications-Table, Accessed on 13 January 2010.
10. Ljungman P, Bregni M, Brune M, Cornelissen J, Witte TD, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (e-pub ahead of print 6 July 2009).
11. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439-449.
12. Subsequent donations, clinical working group, link to projects. http://www.worldmarrow.org. Accessed on 13 January 2010.
13. Cell dose survey response, clinical working group, link to projects. http://www.worldmarrow.org. Accessed on 13 January 2010.
14. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006;135:642-650.
15. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007;137:77-78; author reply 79-80.
16. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006;135:651-652.
17. McCullough J, Kahn J, Adamson J, Anderlini P, Benjamin R, Confer D et al. Hematopoietic growth factors-use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008;48:2008-2025.
18. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004;32:122-130.
19. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008;48:1495-1501.
20. Tulpule S, Shaw BE, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. Bone Marrow Transplant 2009;44:129-130.
21. Wanner M, Bochert S, Schreyer IM, Rall G, Rutt C, Schmidt AH. Losing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation. BMC Health Serv Res 2009;9:2.
22. World Marrow Donor Association (WMDA) Guidelines for couriers and the transportation of haemopoietic progenitor cells (HPC-BM, apheresis and therapeutic cells-T Cells). http://www.worldmarrow.org/fileadmin/WorkingGroups- Subcommittees/DRWG/WMDA-Courier-and-Transportation-Guidelinespdf. Accessed on 13 January 2010.
23. Halter J, Kodera Y, Ispizua AU, Greinix HT, Schmitz N, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009;94:94-101.
24. Holig K, Kramer M, Kroschinsky F, Bornhauser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009;114:3757-3763.
25. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009;113:3604-3611.